Adolor — Technical Presentation (April 2003)
17 slides from Adolor's technical presentation, Apr 2, 2003
Slide 1: Results from Alvimopan Phase 3 Clinical Study 14CL302
adolor CORPORATION Results from Alvimopan Phase 3 Clinical Study 14CL302 April 2, 2003
Slide 2: Forward-Looking Statements
Forward-Looking Statements adolor This oral presentation and the questions and answers that follow contain forward-looking statements including but not limited to the following: + Our ability to submit study 302 in an NDA + Our ability to achieve confirming results in our ongoing Phase 3 studies + O
Slide 3: Alvimopan for the Management of Postoperative Ileus -- Study 14CL302
Alvimopan for the Management of Postoperative _/ AS8BN. Ileus -- Study 14CL302 adelor * Double-blind, placebo-controlled, randomized, multi-center * To enroll 450 patients across 3 treatment groups (alvimopan 6 or 12 mg, or placebo); approximately 150 each « Patients were to receive their first dose
Slide 4: Alvimopan for the Management of Postoperative Ileus -- Inclusion Criteria
Alvimopan for the Management of Postoperative _ adolor Hleus -- Study 1L4CL362 ConPORATION ¢ Inclusion Criteria > Male or Female between 18 and 80 years of age > Partial Colectomy (excluding low anterior resection) or Abdominal Hysterectomy (Radical or Simple) + Simple Hysterectomy limited to 20% >
Slide 5: Alvimopan for the Management of Postoperative Ileus -- Endpoints
Alvimopan for the Management of Postoperative aE Ileus -- Study 14CL302 adolor + Primary Efficacy Endpoint > Time to recovery of gastrointestinal (G.L) function (composite endpoint is upper AND lower G.L recovery) + Time to upper G.I. Recovery: tolerating solid foods + Time to lower G.L Recovery: fl
Slide 6: Specified Primary Endpoint Recovery of GI Function
Specified Primary Endpoint Analysis: Time to Recovery of GI -S88~. Function - Alvimopan Study 14CL302 adolor 6 mgs. placebo: hazard ratio = 1.47, P<0.01 (Cox Proportional Hazard Model) Aprit 2, 2003 6
Slide 7: Additional Recovery of GI Function
Additional Analysis: Time to Recovery of GI Function - 733. Alvimopan Study 14CL302 adolor oa 6mg—, Sa On average, patients treated with 6 mg of alvimopan had os atime to recovery of GI function approx. 76% of that of the placebo group translating to approx. 24 hours earlier « reoovery 2s (Accelerat
Slide 8: Primary Endpoint: Time to Recovery of GI Function
Primary Endpoint: Time to Recovery of GI Function -+ opan Study 14CL302 adolor Postop. _ 100 Day = G15 m>6 8 m6 a z os _ z 50 ad 5 E a3 g ~ 5 a3 2 ol ha Aprit 2, 2003 @
Slide 9: Specified Secondary Endpoint Analysis: Time to Hospital Discharge Order Written
A Specified Secondary Endpoint Anatysis: Time to Hospital yo Discharge Order Written — Alvimopan Study 14CL302 adolor 6 mgs. placebo: hazard ratio = 1.51, P <0.01 (Cox Proportional Hazard Model) Aprit 2, 2003 °
Slide 10: Additional Hospital Discharge Order Written
Additional Analysis: Time to Hospital Discharge —_/ ARB Order Written — Alvimopan Study 14CL302 adolor Pepodon of Subs Aciotng End & i On average, patients treated with 6 mg ofalvimopan had a time to hospital discharge order written approx. 72% of that of the placebo group translating ta approx. 28
Slide 11: Secondary Endpoint: Time to Discharge Order Written
Secondary Endpoint: Time to Discharge Order Written — Alvimopan Study 14CL302 adolor a Postop. = ¥ S75, faneensansaven ket eesseseeen [PG Ben a Bg £e 50 me Ee at a 88 25 ” ge a3 z a 0 {| De! 6 mg Placebo Group Aprit 2, 2003 a
Slide 12: Specified Primary Endpoint Recovery of GI Function (12 mg)
Specified Primary Endpoint Analysis: Time to Recovery of GI Function -- Alvimopan Study 14CL302 © Aprit 2, 2003 ABs adolor 12 mg_ws. placebo: hazard ratio = 1.23, P= 0.11 (Cox Proportional Hazard Model)
Slide 13: Additional Recovery of GI Function (12 mg)
Additional Analysis: Time to Recovery of GI Function — AGS3~ Alvisnopan Study 14CL302 adolor © rer of Suljeco Actesng End & On average, patients treated with 12 mg ofalvimopan had a time to recovery of GI function approx. 85% of that of the placebo group translating ta approx. 15 hours earlier recov
Slide 14: Specified Secondary Endpoint Analysis: Time to Hospital Discharge Order Written (12 mg)
A Specified Secondary Endpoint Anatysis: Time to Hospital yo Discharge Order Written — Alvimopan Study 14CL302 adolor 12mg vs. placebo: hazard ratio = 1.18, P=0.19 294 (Cox Proportional Hazard Model) 12 mg —, Aprit 2, 2003 “
Slide 15: Additional Hospital Discharge Order Written (12 mg)
Additional Analysis: Time to Hospital Discharge Order /A333~ Written — Alvimopan Study 14CL302 adolor 1 on pr Papin of Suljecs Acting Ene & On average, patients treated with 12 mg of alvimopan had a time to hospital discharge order written approx. 83% of that of the placebo group translating to appr
Slide 16: Alvimopan Safety and Adverse Events -- Study 14CL302
Alvimopan for the Management of ABN Postoperative Ileus -- Study 14CL302 adolor « Alvimopan was generally well tolerated * Most frequent adverse events were : Placebo = S mg 12mg n= 153 n= 150 n= 146 Nausea 67.3% 64.0% 56.8% Vomiting 32.0% 25.3% 15.1% Hypotension 15.0% 12.0% 11.6% Discontinuations f
Slide 17: Postoperative Ileus Development Targets
Alvimopan for the Management of ABN Postoperative Ileus -- Study 14CL302 adolor Postoperative Ileus Development Targets Studies Accrual Completion Target 306 Complete 308 Q2 313 Q2 NDA Submission Target Year-end 2003 » NDA submission will depend on achieving confirmatory clinical trial results; and